Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April, Noventure granted Pharmaforce exclusive distribution right for TASECTAN® AF in the Nordic markets. TASECTAN® AF is intended to restore the physiological functions of the intestinal [...]
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore the physiological functions of the intestinal walls. It is specifically formulated for the control and reduction of the symptoms related to diarrheal events of different [...]
New publication for Utipro® Plus We are pleased to announce the publication of a case series referring about the benefits of Utipro® Plus in some challenging cases of urinary infections. In this new publication, that is the result of a fruitful collaboration among KOLs of international relevance, the product has [...]
We are pleased to inform you about our first #webinar sessions❗ On October 30th we talked about #UTIPROPLUS and its use in uncomplicated #UTIs. Some KOLs presented their experiences with the product and spoke about the latest scientific updates on it and some partners shared the best practices and their [...]
Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online: Oct 16, 2020. DOI: 10.1159/000510874 Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online: Oct [...]
Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs in Context 2020; 9: 2020-4-13. DOI: 10.7573/dic.2020-4-13. Free PMC article. Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs in Context 2020; 9: [...]
Cai T et al. Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study. Future Microbiol. 2019 Aug;14:1013-1021. doi: 10.2217/fmb-2019-0145 Cai T et al. Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study. Future Microbiol. 2019 Aug;14:1013-1021. [...]
Utipro® Plus AF available for launch We are pleased to announce the availability for launch of a new formulation of UTIPRO® PLUS, our product for uncomplicated UTIs. This version of the product, totally free from animal derivatives, is commercialized under the brand Utipro® Plus AF, whereas AF stands for Advanced Formulation. In [...]
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Finland. The product is commercialized over the Finnish territory under the umbrella brand UrinCUR / Utipro plus and it is distributed by RFSU, our partner for the product on the Swedish and Norwegian territory [...]
News on NOVENTURE participation at EAU 2019 in BARCELONA For the fourth consecutive year, Noventure was present at the annual congress of the EAU – European Association of Urology- that took place in Barcelona 15th – 19th March 2019. Noventure participation to EAU is to confirm its presence in the [...]